At present, minimally invasive surgical procedures have been widely adopted, and the penetration rate of laparoscopic surgeries has been increasing year by year. This directly drives the continuous rapid growth of the laparoscopic cannula market. A new development pattern has emerged globally, where European and American brands dominate the high-end market, domestic medical devices rise rapidly, centralized procurement promotes the standardization of prices, and technology accelerates the process of domestic autonomy. Johnson & Johnson, Smith & Nephew, and Olympus remain at the top of the global ranks. Domestic manufacturers such as Mindray, Kangji, Weigao, and Bluefan are catching up rapidly and gradually achieving full replacement in the mid-range market and gradually breaking through in the high-end market.

High-end complex visualization, single-port surgery, and elongated and thickened special laparoscopic cannulas have long been monopolized by imported brands. Foreign enterprises possess a complete patent system, long-term clinical data accumulation, and stable and strict quality control. Their products have stronger durability, sealing performance, and compatibility with multiple brand laparoscopic systems. They have long dominated the high-difficulty surgery market in tertiary hospitals, with high brand recognition and premium pricing capabilities. Leveraging a century of experience in surgical instrument research and development, foreign enterprises have a leading edge in metal precision processing, valve sealing technology, and long-term sterilization stability.

The domestic laparoscopic cannula industry has rapidly matured. The use of domestic raw materials, advanced precision injection molding, and five-axis CNC processing technologies has been fully achieved. The core performance of domestic stainless steel, titanium alloy, and medical polymer cannulas has reached the same international level. Relying on localized production, efficient supply chains, affordable prices, and rapid after-sales delivery, domestic brands have rapidly covered secondary hospitals, county-level hospitals, and private medical institutions. After winning the centralized procurement bids, they further expanded their market share. For the mid-range conventional cannulas, 100% domestic substitution has been basically achieved.

The core driving force behind industry growth comes from the popularization of minimally invasive surgical techniques, the increase in gynecological and general surgical procedures, the explosive growth of day surgeries, and the significant increase in the demand for disposable medical supplies due to the enhanced safety requirements for hospital infections. At the same time, single-port laparoscopy and robot-assisted laparoscopy have developed rapidly, driving the continuous rise in demand for miniaturized, intelligent, and multi-channel integrated cannulas, providing manufacturers with new growth opportunities.

The breakthrough path for domestic manufacturers is clear: they focus on customizing for clinical scenarios, upgrading material precision processes, accumulating multi-center clinical data, and laying out core invention patents. Gradually, they break through the technical barriers of foreign companies. In the coming years, high-end reusable laparoscopic cannulas, visual safety puncture cannulas, and robot-specific cannulas will become the main targets for domestic manufacturers. With the continuous improvement of domestic product quality and the continuous tilt of medical insurance policies, the era of complete import substitution for laparoscopic cannulas is accelerating. Domestic enterprises are expected to gradually enter the ranks of global mainstream laparoscopic instrument suppliers.